Founded in 2021, BioMAdvanced Diagnostics is a French start-up spin-off of CR2TI and Nantes University Hospital. The company focuses on identifying biomarkers to assess and predict the risk of transplant rejection, with the goal of improving patient outcomes and reducing costs for healthcare systems. Their molecular diagnostic and biomarker tests provide clinicians with predictive scores and can easily be integrated into standard treatment protocols. Currently, their applications are aimed at improving the follow-up of kidney or lungs transplanted patients. The company recently raised 1.7 million euros in a seed investment round and is supported by Atlanpole and SATT Ouest Valorisation.